These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21220534)

  • 1. In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.
    Sato T; Tateda K; Kimura S; Iwata M; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1588-93. PubMed ID: 21220534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiological profile of telithromycin, the first ketolide antimicrobial.
    Felmingham D
    Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antibacterial activity of modithromycin against streptococci and Haemophilus influenzae.
    Sato T; Kawai Y; Matsuda H; Tateda K; Kimura S; Ishii Y; Yamaguchi K; Gotoh N
    J Antimicrob Chemother; 2011 Jul; 66(7):1547-54. PubMed ID: 21511823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
    Sato T; Tateda K; Kimura S; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1594-7. PubMed ID: 21220530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Flamm RK; Rhomberg PR; Sader HS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
    Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
    J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci.
    Barry AL; Fuchs PC; Brown SD
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):494-7. PubMed ID: 11561807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci.
    Shortridge VD; Zhong P; Cao Z; Beyer JM; Almer LS; Ramer NC; Doktor SZ; Flamm RK
    Antimicrob Agents Chemother; 2002 Mar; 46(3):783-6. PubMed ID: 11850262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.
    Rospide MF; Biedenbach DJ; Jones RN
    Int J Antimicrob Agents; 2001 Jun; 17(6):451-5. PubMed ID: 11397614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
    Okubo T; Iyobe S; Fujiki Y; Sagai H
    Jpn J Antibiot; 2003 Jun; 56(3):163-70. PubMed ID: 12942787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.
    Abbanat D; Webb G; Foleno B; Li Y; Macielag M; Montenegro D; Wira E; Bush K
    Antimicrob Agents Chemother; 2005 Jan; 49(1):309-15. PubMed ID: 15616310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.
    O'Dwyer K; Hackel M; Hightower S; Hoban D; Bouchillon S; Qin D; Aubart K; Zalacain M; Butler D
    Antimicrob Agents Chemother; 2013 May; 57(5):2333-42. PubMed ID: 23478958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
    Bemer-Melchior P; Juvin ME; Tassin S; Bryskier A; Schito GC; Drugeon HB
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2999-3002. PubMed ID: 11036012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.